BALDING
REFERENCES
1. Birch MP, Messenger AG. Genetic factors predispose to balding and
non-balding in men. Eur J Dermatol. 2001 Jul;11(4):309-14.
2. Stene JJ. [Alopecia areata and treatment]. Rev Med Brux. 2004 Sep;25(4):A282-A285.
3. Price VH. Androgenetic alopecia in adolescents. Cutis. 2003 Feb;71(2):115-21.
4. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle.
J Dermatol Sci. 2004 Jun;35(1):9-18.
5. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle.
J Dermatol Sci. 2004 Jun;35(1):9-18.
6. Whiting DA. Chronic telogen effluvium. Dermatol Clin. 1996 Oct;14(4):723-31.
7. Hadshiew IM, Foitzik K et al. Burden of hair loss: stress and the
underestimated psychosocial impact of telogen effluvium and androgenetic
alopecia. J Invest Dermatol. 2004 Sep;123(3):455-7.
8. Murray JC. Pregnancy and the skin. Dermatol Clin. 1990 Apr;8(2):327-34.
9. Gollnick H, Blume U et al. [Adverse drug reactions on hair]. Z
Hautkr. 1990 Dec;65(12):1128-34.
10. Pierard-Franchimont C, Pierard GE. [How I explore...Hair loss
in cancer patients]. Rev Med Liege. 2004 Sep;59(9):525-9.
11. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune
basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
12. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune
basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
13. Yamada K, Goto S. Bilateral subthalamic nucleus stimulation results
in reversal of alopecia in Parkinson's disease. Parkinsonism Relat Disord.
2004 Aug;10(6):353-5.
14. Borum ML, Cannava M. Diffuse alopecia associated with omeprazole.
Am J Gastroenterol. 1997 Sep;92(9):1576.
15. Sarris E, Tsele E et al. Diffuse alopecia in a hemodialysis patient
caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis.
2003 May;41(5):E15.
16. Ettefagh L, Nedorost S et al. Alopecia areata in a patient using
infliximab: new insights into the role of tumor necrosis factor on human
hair follicles. Arch Dermatol. 2004 Aug;140(8):1012.
17. Gottenberg JE, Venancie PY et al. Alopecia areata in a patient
with rheumatoid arthritis treated with leflunomide. J Rheumatol. 2002
Aug;29(8):1806-7.
18. Chave TA, Mortimer NJ et al. Agranulocytosis and total scalp alopecia
following acitretin. Br J Dermatol. 2003 May;148(5):1063-4.
19. Kohno Y, Ishii A et al. [A case of hair loss induced by carbamazepine].
Rinsho Shinkeigaku. 2004 Jun;44(6):379-81.
20. Gautam M. Alopecia due to psychotropic medications. Ann Pharmacother.
1999 May;33(5):631-7.
21. Shelley ED, Shelley WB. Alopecia and drug eruption of the scalp
associated with a new beta-blocker, nadolol. Cutis. 1985 Feb;35(2):148-9.
22. Hashimoto K. The structure of human hair. Clin Dermatol. 1988
Oct;6(4):7-21.
23. Paus R, Foitzik K. In search of the "hair cycle clock":
a guided tour. Differentiation. 2004 Dec;72(9-10):489-511.
24. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002
Dec 30;198(1-2):89-95.
25. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune
basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
26. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune
basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
27. Drake L, Hordinsky M et al. The effects of finasteride on scalp
skin and serum androgen levels in men with androgenetic alopecia. J
Am Acad Dermatol. 1999 Oct;41(4):550-4.
28. FMPHLSG., The Finasteride Male Pattern Hair Loss Study Group.
Long-term (5-year) multinational experience with finasteride 1 mg in
the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.
29. Pitts WR, Jr. Finasteride (Propecia) and the promotion of high-grade
prostate cancer. Arch Dermatol. 2004 Jul;140(7):885-6.
30. Bramson HN, Hermann D et al. Unique preclinical characteristics
of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997
Sep;282(3):1496-502.
31. Ellis CN, Brown MF et al. Sulfasalazine for alopecia areata. J
Am Acad Dermatol. 2002 Apr;46(4):541-4.
32. Burke KE. Hair loss. What causes it and what can be done about
it. Postgrad Med. 1989 May 1;85(6):52-73, 77.
33. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol.
2002 Jul;27(5):396-404.
34. Shimizu Y, Sakai M et al. Immunohistochemical localization of
nitric oxide synthase in normal human skin: expression of endothelial-type
and inducible-type nitric oxide synthase in keratinocytes. J Dermatol.
1997 Feb;24(2):80-7.
35. Prager N, Bickett K et al. A randomized, double-blind, placebo-controlled
trial to determine the effectiveness of botanically derived inhibitors
of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern
Complement Med. 2002 Apr;8(2):143-52.
36. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase
isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate.
Biochem Biophys Res Commun. 1995 Sep 25;214(3):833-8.
37. Cos P, De Bruyne T et al. Proanthocyanidins in health care: current
and new trends. Curr Med Chem. 2004 May;11(10):1345-59.
38. Neve HJ, Bhatti WA et al. Reversal of Hair Loss following Vertical
Gastroplasty when Treated with Zinc Sulphate. Obes Surg. 1996 Feb;6(1):63-5.
39. Uno H, Kurata S. Chemical agents and peptides affect hair growth.
J Invest Dermatol. 1993 Jul;101(1 Suppl):143S-7S.
|